Protein-Serine-Threonine Kinases - Mechanistic Target of Rapamycin Complex 2 PubMed MeSh Term

Overview

subject area of

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors Journal Article

broader concept

Protein-Serine-Threonine Kinases - TOR Serine-Threonine Kinases PubMed MeSh Term